← All companies

IBRX

ImmunityBio, Inc.

IBRX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$7.15

-0.30 -4.03%

Key statistics

from XBRL data in SEC filings

Market cap

$7.58B

Revenue (TTM)

$166M

Net income (TTM)

-$992M

EPS (TTM)

$-0.97

P/E ratio

—

Dividend yield

—

Free cash flow

-$309M

Cash

$75.7M

Total assets

$629M

Gross margin

—

52-week range

$1.95 – $12.43

Recent SEC filings

40 most recent

Annual, quarterly & current reports

10-Q Quarter ended 2026-06-30 Aug 4, 2026 8-K Results of operations (earnings release) Aug 4, 2026 8-K Regulation FD disclosure Jul 30, 2026 8-K Shareholder vote results Jun 10, 2026 8-K Entered a material agreement; Regulation FD disclosure May 18, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 8-K Results of operations (earnings release) Apr 9, 2026 8-K Regulation FD disclosure Apr 6, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Regulation FD disclosure; Other events Mar 31, 2026 10-K Fiscal year ended 2025-12-31 Feb 23, 2026 8-K Results of operations (earnings release) Feb 23, 2026 8-K Other events Feb 18, 2026 8-K Entered a material agreement Jan 26, 2026 8-K Results of operations (earnings release) Jan 15, 2026 8-K Other events Jan 14, 2026 8-K Entered a material agreement; Other events Dec 29, 2025 8-K Director or officer change Dec 15, 2025 8-K Other events Dec 12, 2025 10-Q Quarter ended 2025-09-30 Nov 5, 2025 8-K Results of operations (earnings release) Nov 5, 2025 8-K Other events Aug 8, 2025 10-Q Quarter ended 2025-06-30 Aug 5, 2025 8-K Results of operations (earnings release) Aug 5, 2025 8-K Entered a material agreement; Results of operations (earnings release); Regulation FD disclosure; Other events Jul 25, 2025 8-K Director or officer change; Shareholder vote results Jun 20, 2025 10-Q Quarter ended 2025-03-31 May 12, 2025 8-K Results of operations (earnings release) May 12, 2025 8-K Other events May 5, 2025 8-K Results of operations (earnings release) Apr 15, 2025 8-K Entered a material agreement; Regulation FD disclosure Apr 8, 2025 8-K Changed accountants Mar 19, 2025 10-K Fiscal year ended 2024-12-31 Mar 3, 2025 8-K Results of operations (earnings release) Mar 3, 2025 8-K Director or officer change Feb 13, 2025 8-K Director or officer change Feb 7, 2025 8-K Entered a material agreement; Other events Dec 11, 2024 8-K Other events Dec 10, 2024 8-K Other events Nov 19, 2024 10-Q Quarter ended 2024-09-30 Nov 12, 2024